[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Oxford University Clinical Research Unit Indonesia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":130},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,58,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100632149","empowerment-training-for-personal-agency-development-of-primary-health-care-workers-100632149",false,"NCT07509931","Empowerment Training for Personal Agency Development of Primary Health Care Workers","Strengthening Personal Agency and Service Performance Among Primary Health Care Workers Through a Complex Empowerment Intervention","Inclusion Criteria:\n\n\\- Registered staff of the intervention clusters (PHCs), either as registered civil servant, contract workers, or honorary workers.\n\nExclusion Criteria:\n\n* PHC staff who decline to provide informed consent.\n* PHC staff who will not retain their employment until the end of the observation period.\n* Participants who are not in good physical and mental condition to attend the training intervention (for the intervention arm).","ALL",{"count":18,"type":19},200,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study evaluates an Empowerment Agency Training (EAT) intervention within the SPHERES programme that aims to strengthen personal agency among workers in primary healthcare centers (Puskesmas) in Indonesia. The intervention focuses on building self-efficacy, behavioural control, leadership, and intentional decision-making through structured training, follow-up action planning, observational support, and sustainability-oriented incentives. Strengthening personal agency is expected to improve the use of data for decision-making and the delivery of priority primary health services at the Puskesmas level.",[25,26,27,28,29],"Data Accuracy","Agency","Burnout","Service Evaluation","Assertiveness",[31,32,33,34,35,27,36,37,38,39,40,41,42,43,44],"Personal agency","Empowerment training","Primary health care","Health workforce","Behaviour change","Data utilisation","Digital health","Health systems","Complex intervention","Randomised controlled trial","Observation","Service delivery improvement","Implementation research","Indonesia","NOT_YET_RECRUITING","2026-03-29",{"date":48,"type":49},"2026-04-03","ACTUAL",{"date":51,"type":19},"2026-04-10",{"date":53,"type":19},"2026-12-31",{"name":55,"class":56},"Oxford University Clinical Research Unit Indonesia","OTHER",2,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":20,"phases":69,"briefSummary":70,"conditions":71,"keywords":78,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":57},"100602632","scalable-public-health-empowerment-research-and-education-sites-spheres-100602632","NCT07126041","Scalable Public Health Empowerment, Research, and Education Sites (SPHERES)","End-to-end Digital Transformation for Primary Health Care Performance Management Via Scalable Public Health Empowerment, Research, and Education Sites: A Stepped-Wedge Cluster Randomized Trial","SPHERES","Inclusion Criteria:\n\n* Residing in or participating in the district catchment areas\n* Receiving services from participating health care facilities\n* Health providers and district health officials consent to participate in data collection\n\nExclusion Criteria:\n\n* Individuals (health workers or patients) who decline to provide informed consent.\n* Individuals who are not directly involved in or accessing services from health care facilities or district health offices.\n* Inability to provide consent due to cognitive impairment or acute illness for health workers or district health officials involved in data collection",true,{"count":68,"type":19},1750000,[22],"SPHERES is a health service research trial in the Indonesian primary care system designed to improve health system performance using a structured data-driven action model. The intervention empowers district health leaders to make data-informed decisions that will enhance outcomes across maternal, child, infectious, and non-communicable disease programs.",[72,73,74,75,76,77],"Pregnancy","Neonatal Mortality","Tuberculosis","Hepatitis B","Hypertension","Diabetes Mellitus",[79,80,81,82,83,84,74,75,85,76,86,44,87,88,89],"Primary health care performance","Digital health transformation","Maternal health","Child health","Immunization","Stunting","Diabetes mellitus","Health system strengthening","Health governance","Human resource management","Work culture","2025-08-09",{"date":92,"type":49},"2025-08-15",{"date":94,"type":19},"2025-08-14",{"date":96,"type":19},"2027-03-31",{"name":55,"class":56},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":20,"phases":110,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100457979","phase-2-efficacy-and-tolerability-of-adjunct-metformin-for-multibacillary-leprosy-100457979","NCT05243654","Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy","Efficacy and Tolerability of Adjunct Metformin in Combination With Multidrug Treatment for Multibacillary Leprosy: A Randomized Double-blind, Controlled Proof-of-Concept Phase 2 Trial in Indonesia","MetLep","Inclusion Criteria:\n\n* Participant is a male or female, aged ≥18 and ≤65 years.\n* Participant is newly diagnosed with MB leprosy and has been receiving MDT ≤ 28 days.\n* Participant is willing and able to give informed consent for participation in the trial.\n* Participant is willing to adhere to study follow-up schedule for 48 weeks.\n\nExclusion Criteria:\n\n* Participant has received MDT \\>28 days for the current episode of MB leprosy, prior to study enrolment.\n* Presence of leprosy reaction and\u002For nerve function impairment requiring systemic corticosteroids on screening\u002Fenrolment evaluation.\n* Participants who have been treated for leprosy in the past.\n* Chronic systemic corticosteroid use for any other medical condition on screening evaluation (chronic use defined as ≥ 2 weeks).\n* History of diabetes mellitus or diabetes mellitus diagnosed on screening evaluation (random blood glucose is elevated ≥200 mg\u002FdL (or ≥11,1 mmol\u002FL) or fasting blood glucose ≥ 126 mg\u002FdL (or ≥7.0 mmol\u002FL)).\n* History of hypoglycaemia (random blood glucose \\\u003C55 mg\u002FdL (or \\\u003C3.0 mmol\u002FL).\n* History of cardiac failure, ischaemic heart disease, alcoholism, history of lactic acidosis or states associated with lactic acidosis such as shock or pulmonary insufficiency, and conditions associated with hypoxia.\n* History of intolerance or hypersensitivity to metformin.\n* Estimated glomerular filtration rate (eGFR) ≤30 mL\u002Fmin\u002F1.73m2 calculated by the CKDEPI equation.\n* AST or ALT ≥3 times the upper limit of normal (ULN) on screening evaluation.\n* Any serious medical condition for which participation in the trial, as judged by the investigator or treating physician, could compromise the well-being of the subject or prevent, limit or confound protocol-specified assessments.\n* HIV-positive on screening evaluation.\n* Female participant of childbearing age who is pregnant (clinically confirmed or urine dipstick for human chorionic gonadotrophin hormone) or breastfeeding.\n* Use of metformin within 12 weeks prior to study enrolment.\n* Use of other regular hypoglycaemic agents, including insulin.\n* Participation in another research trial involving an investigational product within 12 weeks prior to study enrolment.","18 Years","65 Years",{"count":109,"type":19},166,[111],"PHASE2","This trial aims to evaluate the efficacy, tolerability and safety of adjunct metformin added to standard-of-care multi-drug therapy (MDT) in patients with multibacillary leprosy, and explore its effects on immunological endpoints. A double-blind, placebo controlled proof-of-concept trial will be performed in which patients with newly diagnosed multibacillary leprosy will be randomized (1:1) to metformin 1000mg OD versus placebo for 24 weeks in addition to MDT during 48 weeks.\n\nThe main research question is whether adjunctive metformin, combined with MDT, will improve the clinical outcomes of patients with multibacillary leprosy by mitigating leprosy reactions, thereby reducing nerve damage and corticosteroid use and its associated morbidity. The second aim is to explore whether adjunct metformin, added to MDT, has an acceptable tolerability and safety in patients with multibacillary leprosy.",[114,115,116],"Leprosy","Leprosy, Multibacillary","Neglected Tropical Diseases",[114,118,119],"Multibacillary leprosy","Skin-NTD","RECRUITING","2025-08-04",{"date":123,"type":49},"2025-08-07",{"date":125,"type":49},"2022-10-01",{"date":127,"type":19},"2026-09-30",{"name":55,"class":56},6,""]